May 29, 2017 9:53 AM ET

Pharmaceuticals

Company Overview of Nanotherapeutics, Inc.

Company Overview

Nanotherapeutics, Inc. manufactures and develops biopharmaceutical products. The company is engaged in the pre-clinical and clinical development, formulation optimization, and cGMP manufacture of biopharmaceutical products and medical devices. The company develops biodefense medical countermeasures, CNS, wound healing, addiction and pain, oncology, anti-infective, vaccines, and orthopedics products. It offers development, manufacturing, analytical, and collaboration services. Nanotherapeutics, Inc. has a strategic alliance with PharmAthene Inc. The company was formerly known as Nanocoat Technologies, Inc. and changed its name to Nanotherapeutics, Inc. in July 2002. The company was founded in...

13859 Progress Boulevard

Suite 300

Alachua, FL 32615

United States

Founded in 1999

Phone:

386-462-9663

Fax:

386-462-2087

Key Executives for Nanotherapeutics, Inc.

Chief Executive Officer and President
Co-Founder, Director and Member of the Advisory Board
Chief Financial Officer and Director
Age: 62
Senior Vice President of Operations
Senior Vice President of Preclinical Development & QA and Company Secretary
Compensation as of Fiscal Year 2016.

Nanotherapeutics, Inc. Key Developments

Battelle and Nanotherapeutics Form Alliance to Speed Up Process of Industry Bringing Medical Countermeasures to Market

Battelle and Nanotherapeutics, Inc. announced that the organizations have entered an alliance to bring together core research, development, test and evaluation and manufacturing capabilities needed to expedite the development of medical countermeasures urgently required by the Department of Defense to protect deployed military forces from CBRN threats.

Trethera Corp. and Nanotherapeutics Enter Pact for Rights to Triapine in Hematological Malignancies

Trethera Corp. and Nanotherapeutics reported the signing of an exclusive worldwide agreement whereby Nanotherapeutics has granted Trethera an exclusive license for the global development, manufacturing and marketing of Triapine (3-AP) and all formulations, for the treatment of hematological malignancies. Triapine is a clinical-stage, small molecule inhibitor of ribonucleotide reductase (RNR), a key enzyme in the de novo pathway of nucleotide biosynthesis.

Trethera Corporation and Nanotherapeutics Sign Exclusive Worldwide Agreement for Rights to Triapine® in Hematological Malignancies

Trethera Corporation and Nanotherapeutics, Inc. announced the signing of an exclusive worldwide agreement whereby Nanotherapeutics has granted Trethera an exclusive license for the global development, manufacturing and marketing of Triapine® (3-AP) and all formulations, for the treatment of hematological malignancies. Triapine® is a clinical-stage, small molecule inhibitor of ribonucleotide reductase (RNR), a key enzyme in the de novo pathway of nucleotide biosynthesis. Trethera has advanced preclinical development of proprietary, small molecule inhibitors of deoxycytidine kinase (dCK), the rate-limiting enzyme in the salvage pathway of nucleotide biosynthesis. Results of its preclinical studies indicate robust and durable anti-leukemic activity of its dCK inhibitors when combined with inhibitors of RNR, and these combinations have demonstrated superior activity over single agent treatments. Trethera aims to commence a Phase I clinical trial for its orally administered, lead dCK inhibitor, TRE-515, in H2 2017.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
April 25, 2017
Nanotherapeutics Bohumil s.r.o.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Nanotherapeutics, Inc., please visit www.nanotherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.